Looking at the proteases from a simple perspective

Journal of Molecular Recognition

Volumn 24, Issue 2, 2011, Pages 165-181

  Castro, Helena C ^a   Abreu, Paula A ^a   Geraldo, Reinaldo B ^a   Martins, Rita C A ^a   Dos Santos, Ruben ^a   Loureiro, Natália I V ^a   Cabral, Lúcio M ^a   Rodrigues, Carlos R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

HIV 1 protease; inhibitors; MMP1 and cruzain; proteases; thrombin

Indexed keywords

CYSTEINE PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; MATRIX METALLOPROTEINASE; PEPTIDE HYDROLASE; SERINE PROTEINASE;

CHEMISTRY; HUMAN; METABOLISM; REVIEW;

CYSTEINE ENDOPEPTIDASES; HIV PROTEASE; HUMANS; MATRIX METALLOPROTEINASES; PEPTIDE HYDROLASES; SERINE PROTEASES;

HUMAN IMMUNODEFICIENCY VIRUS 1; TRYPANOSOMA CRUZI;

EID: 79952182365     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.1091     Document Type: Review

References (318)

1. Acharya MR, Venitz J, Figg WD, et al,. 2004. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug. Resist. Updat. 7: 195-208. (Pubitemid 39024520)
2. Ala PJ, Huston EE, Klabe RM, et al,. 1997. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36: 1573-1580. (Pubitemid 27086253)
3. Ala-aho R, Kahari VM,. 2005. Collagenases in cancer. Biochimie 87: 273-286. (Pubitemid 40387606)
4. Amadesi S, Bunnett N,. 2004. Protease-activated receptors: protease signaling in the gastrointestinal tract. Curr. Opin. Pharmacol. 4: 551-556. (Pubitemid 40267867)
5. Aparicio IM, Scharfstein J, Lima AP,. 2004. A new cruzipain-mediated pathway of human cell invasion by Trypanosoma cruzi requires trypomastigote membranes. Infect. Immun. 72: 5892-5902. (Pubitemid 39303702)
6. Asboth B, Polgar L,. 1983. Transition-state stabilization at the oxyanion binding sites of serine and thiol proteinases: hydrolyses of thiono and oxygen esters. Biochemistry 22: 117-122.
7. Asboth B, Stokum E, Khan I, et al,. 1985. Mechanism of action of cysteine proteinases: oxyanion binding site is not essential in the hydrolysis of specific substrates. Biochemistry 24: 606-609. (Pubitemid 15142247)
8. Ashorn P, McQuade TJ, Thaisrivongs S, et al,. 1990. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. USA 87: 7472-7476. (Pubitemid 20341738)
9. Azzam HS, Arand G, Lippman ME, et al,. 1993. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J. Natl. Cancer Inst. 85: 1758-1764. (Pubitemid 23320847)
10. Badimon L, Badimon JJ, Lassila R, et al,. 1991. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 78: 423-434.
11. Badimon L, Meyer BJ, Badimon JJ,. 1994. Thrombin in arterial thrombosis. Haemostasis 24: 69-80. (Pubitemid 24234485)
12. Baines KJ, Wood LG, Gibson PG,. 2009. The nutrigenomics of asthma: molecular mechanisms of airway neutrophilia following dietary antioxidant withdrawal. OMICS 13: 355-365.
13. Baldino CM, Coffen DL, Chipman SD, et al,. 2000. US Patent.
14. Baragi VM, Fliszar CJ, Conroy MC, et al,. 1994. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. J. Biol. Chem. 269: 12692-12697.
15. Barrett AI, Kirschke H, Cathepsin B, Cathepsin H, Cathepsin L,. 1981. Methods Enzymol. 80: 535-561.
16. Barrett AJ, Rawlings ND,. 2001. Evolutionary lines of cysteine peptidases. Biol. Chem. 382: 727-733. (Pubitemid 32631709)
17. Barry M, Gibbons S, Back D, Mulcahy F,. 1997. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32: 194-209. (Pubitemid 27122520)
18. Bar-Shavit R, Kahn A, Fenton JW, et al,. 1983a. Chemotactic response of monocytes to thrombin. J. Cell Biol. 96: 282-285. (Pubitemid 13155586)
19. Bar-Shavit R, Kahn A, Wilner GD, et al,. 1983b. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 220: 728-731. (Pubitemid 13081951)
20. Baum B, Mohamed M, Zayed M, Gerlach C, Heine A, Hangauer D, Klebe G,. 2009. More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the s1 pocket of thrombin. J. Mol Biol. 1: 56-69.
21. Becker DL, Fredenburgh JC, Stafford AR, et al,. 1999. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II. J. Biol. Chem 274: 6226-6233. (Pubitemid 29111032)
22. Becker RC,. 2005. Antithrombotic therapy: an abbreviated reference for clinicians. Am. Heart. J. 155: 149-161.
23. Bernfield M, Kokenyesi R, Kato M, et al,. 1992. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev. Cell. Biol. 8: 365-393. (Pubitemid 23001002)
24. Berry CN, Girardot C, Lecoffre C, et al,. 1994. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb. Haemost. 72: 381-386. (Pubitemid 24280776)
25. Berti P, Storer AJ,. 1995. Alignment/phylogeny of the papain superfamily of cysteine proteases. Mol. Biol. 246: 273-283.
26. Bertini I, Calderone V, Cosenza M, et al,. 2005. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc. Natl. Acad. Sci. USA 102: 5334-5339. (Pubitemid 40530258)
27. Birkedal-Hansen H, Moore WG, Bodden MK, et al,. 1993. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4: 197-250. (Pubitemid 23103292)
28. Blavier L, Patrick I, Declerck S, et al,. 1999. Tissue inhibitors of matrix metalloproteinases in cancer. Ann. N.Y. Acad. Sci. 878: 108-119. (Pubitemid 29353563)
29. Blundell TL, Lapatto R, Wilderspin AF, et al,. 1990. The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. Trends Biochem. Sci. 15: 425-430. (Pubitemid 20376581)
30. Bode W,. 2006. Structure and interaction modes of thrombin. Blood Cells Mol. Dis. 36: 122-130.
31. Bode W, Stubbs MT,. 1993. Spatial structure of thrombin as a guide to its multiple sites of interaction. Semin. Thromb. Hemost. 19: 321-333. (Pubitemid 24023332)
32. Borkakoti N,. 2004. Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. Trans. 32: 17-20. (Pubitemid 38283005)
33. Bott R, Subramanian E, Davies DR,. 1982. Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5-A resolution. Biochemistry 21: 6956-6962.
34. Bouzide A, Sauvé G, Yelle J,. 2005. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies. Bioorg. Med. Chem. Lett. 15: 1509-1513. (Pubitemid 40269022)
35. Brak K, Doyle PS, McKerrow JH, Ellman JA,. 2008. Identification of a new class of nonpeptidic inhibitors of cruzain. J. Am. Chem. Soc. 130: 6404-6410. (Pubitemid 351706101)
36. Brighton TA,. 2004. The direct thrombin inhibitor melagatran/ ximelagatran. Med. J. Aust. 181: 432-437. (Pubitemid 39419749)
37. Brinen LS, Hansell E, Cheng J, et al,. 2000. A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease. Structure 8: 830-831.
38. Brocklehurst K,. 1979. The equilibrium assumption is valid for the kinetic treatment of most time-dependent protein-modification reactions. Biochem. J. 181: 775-778.
39. Bromme D, Bonneau PR, Purisima E, et al,. 1996. Contribution to activity of histidine-aromatic, amide-aromatic, and aromatic-aromatic interactions in the extended catalytic site of cysteine proteinases. Biochemistry 35: 3970-3979. (Pubitemid 26113452)
40. Brower ET, Bacha UM, Kawasaki Y, et al,. 2008. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem. Biol. Drug Des. 71: 298-305. (Pubitemid 351347797)
41. Brown PD, Bloxidge RE, Stuart NSA, et al,. 1993. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J. Natl. Cancer Inst. 85: 574-578. (Pubitemid 23110933)
42. Caffrey CR, Scory S, Steverding D,. 2000. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets 1: 155-162.
43. Campetella OE, Martinez J, Cazzulo JJ,. 1990. A major cysteine proteinases is developmentally regulated in Trypanosonma cruzi. FEMS Microbiol. Lett. 67: 145-150.
44. Campetella OE, Henriksson J, Aslund L, et al,. 1992. The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is encoded by multiple polymorphic tandemly organized genes located on different chromosomes. Mol. Biochem. Parasitol. 50: 225-234.
45. Castro HC, Dutra DL, Oliveira-Carvalho AL, et al,. 1998. Bothroalternin, a thrombin inhibitor from the venom of Bothrops alternatus. Toxicon 36: 1903-1912. (Pubitemid 28532768)
46. Castro HC, Loureiro NI, Pujol-Luz M, et al,. 2006. HIV-1 reverse transcriptase: a therapeutical target in the spotlight. Curr. Med. Chem. 13: 313-324.
47. Cazzulo JJ, Couso R, Raimondi A, et al,. 1989. Further characterization and partial amino acid sequence of a cysteine proteinase from Trypanosoma cruzi. Mol. Biochem. Parasitol. 33: 33-41. (Pubitemid 19044514)
48. Cazzulo JJ, Stoka V, Turk V,. 1997. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi. Biol. Chem. 378: 1-10. (Pubitemid 27083501)
49. Cazzulo JJ,. 2002. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. Curr. Top Med. Chem. 2: 1261-1271.
50. Cequier A, Maristany J, Gõmez-Hospital J, Iráculis E, Jara F, Esplugas E,. 2006. Inhibidores directos de la trombina en el intervencionismo coronario percutáneo. Bivalirudina Ver Espan de Cardiol Supl. 6: 18H-28H. (Pubitemid 350070655)
51. Chambers AF, Matrisian LM,. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89: 1260-1270. (Pubitemid 27371946)
52. Chau I, Rigg A, Cunningham D,. 2003. Matrix metalloproteinase inhibitors-an emphasis on gastrointestinal malignancies. Crit. Rev. Oncol. Hematol. 45: 151-176. (Pubitemid 36216311)
53. Chen X, Ren S, Ma MG, et al,. 2003. Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. Atherosclerosis 169: 31-40. (Pubitemid 36830921)
54. Choe Y, Brinen LS, Price MS, et al,. 2005. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorg. Med. Chem. 13: 2141-2156. (Pubitemid 40261134)
55. Clavel F, Hance AJ,. 2004. HIV drug resistance. N. Engl. J. Med. 350: 1023-1035. (Pubitemid 38269279)
56. Condra JH, Schleif WA, Blahy OM, et al,. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
57. Cornish-Bowden AJ, Knowles JR,. 1969. The pH-dependence of pepsin-catalysed reactions. Biochem. J. 113: 353-362.
58. Coussens LM, Fingleton B, Matrisian LM,. 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392. (Pubitemid 34270240)
59. Crawford S, Goff SP,. 1985. A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J. Virol. 53: 899-907. (Pubitemid 15173299)
60. Cunha EF, Sippl W, de Castro Ramalho, Ceva T, Antunes OA, de Alencastro RB, Albuquerque MG,. 2009. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. Eur J Med Chem. 44: 4344-4352.
61. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F,. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. ANRS 109 Study Group. PLoS Pathog. 5: e 1000345.
62. Dang OD, Vindigni A, Di Cera E,. 1995. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc. Natl. Acad. Sci. USA 92: 5977-5981.
63. Darke PL, Huff JR,. 1994. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharm. 25: 399-454.
64. Davies DR,. 1990. The structure and function of the aspartic proteinases. Annu. Rev. Biophys. Chem. 19: 189.
65. Di Cera E, Guinto ER, Vindigni A, et al,. 1995. The Na+ binding site of thrombin. J Biol. Chem. 27: 22089-22092.
66. Di Cera E,. 2003. Thrombin interactions. Chest 124: 11-17.
67. Di Cera E,. 2004. Thrombin: a paradigm for enzymes allosterically activated by monovalent cations. C.R. Biol. 327: 1065-1076. (Pubitemid 40029103)
68. Di Cera E,. 2008. Thrombin. Mol. Aspects Med. 29: 203-254.
69. Diamond SL,. 2007. Methods for mapping protease specificity. Curr. Opin. Chem. Biol. 11: 46-51. (Pubitemid 46223545)
70. Dorsey BD, Levin RB, Mcdaniel SL, et al,. 1994. Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. J. Med. Chem. 37: 3443-3499.
71. Du X, Guo C, Hansell E, et al,. 2002. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. 45: 2695-2707. (Pubitemid 34627642)
72. Eakin AE, Mills AA, Harth G, et al,. 1992. The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi. J. Biol. Chem. 267: 7411-7420.
73. Eder J, Hommel U, Cumin F, et al,. 2007. Aspartic proteases in drug discovery. Curr. Pharm. Des. 13: 271-285. (Pubitemid 46085279)
74. Egeblad M, Werb Z,. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2: 161-174. (Pubitemid 37328786)
75. Eikelboom J,. 2003. Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. ACP J Club 138: 33.
76. Ellis V, Murphy G,. 2001. Cellular strategies for proteolytic targeting during migration and invasion. FEBS Lett. 506: 1-15.
77. Endo K, Takino T, Miyamori H, et al,. 2003. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278: 40764-40770. (Pubitemid 37280893)
78. Enenkel C, Wolf DJ,. 1993. BLH1 codes for a yeast thiol aminopeptidase, the equivalent of mammalian bleomycin hydrolase. Biol. Chem. 268: 7036-7043. (Pubitemid 23105588)
79. Engel JC, Doyle PS, Hsieh I, et al,. 1998. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Exp. Med. 188: 725-734. (Pubitemid 28387935)
80. Engel JC, Doyle PS, Palmer J, et al,. 1998. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell. Sci. 111: 597-606. (Pubitemid 28142364)
81. Erickson JW, Burt SK,. 1996. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36: 545-571. (Pubitemid 26169902)
82. Eriksson BI, Dahl OE,. 2004. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors. Drugs 64: 577-595. (Pubitemid 38482439)
83. Eron JJ, Murphy RL, Peterson D, et al,. 2000. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 14: 1601-1610.
84. Esmon CT,. 1995. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 9: 946-955.
85. Evans HC, Perry CM, Faulds D,. 2004. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 64: 649-675.
86. Fear G, Komarnytsky S, Raskin I,. 2007. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol. Ther. 113: 354-368. (Pubitemid 46149049)
87. Fei X, Zheng QH, Liu X, et al,. 2003. Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorg. Med. Chem. Lett. 13: 2217-2222. (Pubitemid 36700413)
88. Ferrell WR, Lockhart JC, Kelso EB, et al,. 2003. Essential role for proteinase-activated receptor-2 in arthritis. J. Clin. Invest. 111: 35-41. (Pubitemid 36134846)
89. Fitzgerald PM, Springer JP,. 1991. Structure and function of retroviral proteases. Annu. Rev. Biophys. Biophys. Chem. 20: 299-320.
90. Flexner C,. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338: 1281-1292. (Pubitemid 28216584)
91. Foda HD, Zucker S,. 2001. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov. Today 6: 478-482. (Pubitemid 32422151)
92. Foje K, Hanzlik R,. 1994. Peptidyl thioamides as substrates and inhibitors of papain, and as probes of the kinetic significance of the oxyanion hole. Biochim. Biophys. Acta. 1201: 447-453. (Pubitemid 24378053)
93. Fortier S, Touaibia M, Lord-Dufour S, et al,. 2008. Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. Glycobiology 18: 195-204. (Pubitemid 351168258)
94. Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, et al,. 2000. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 404: 518-525. (Pubitemid 30186897)
95. Fujii N, Mallari JP, Hansell EJ, et al,. 2005. Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg. Med. Chem. Lett. 15: 121-123. (Pubitemid 39575795)
96. Gabriel D, Busso N, So A, van den Bergh H, Gurny R, Lange N,. 2009. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. J Control Release. 3: 225-234.
97. Garcia-Touchard A, Henry TD, Sangiorgi G, et al,. 2005. Extracellular proteases in atherosclerosis and restenosis. Arterioscler. Thromb. Vasc. Biol. 25: 1119-1127. (Pubitemid 40776597)
98. Gandhi PS, Chen Z, Di Cera E,. 2010. Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J. Biol. Chem. 285 (20): 15393-15398. Epub 17 March 2010.
99. Gilles A, Keil B,. 1984. Evidence for an active-center cysteine in the SH-proteinase alpha-clostripain through use of N-tosyl-L-lysine chloromethyl ketone. FEBS Lett. 173: 58-62.
100. Gillmor SA, Craick CS, Fletterick RJ,. 1997. Structural determinants of specificity in the cysteine protease cruzain. Protein Sci. 6: 1603-1611. (Pubitemid 27333063)
101. Glasspool RM, Twelves CJ,. 2001. Matrix metalloproteinase inhibitors: past lessons and future prospects in breast cancer. Breast 10: 368-378. (Pubitemid 33061857)
102. Gottlinger HG, Sodroski JG, Haseltine WA,. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86: 5781-5785. (Pubitemid 19217537)
103. Green DW, Ayknet S, Gierse JK, et al,. 1990. Substrate specificity of recombinant human renal renin: effect of histidine in the P2 subsite on pH dependence. Biochemistry 29: 3126-3133. (Pubitemid 20119312)
104. Gross J, Lapiere CM,. 1962. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA 48: 1014-1022.
105. Gurm HS, Bhatt DL,. 2005. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am. Heart. J. 149: 43-53.
106. Gustafsson D, Elg M,. 2003. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res. 109: 9-15.
107. Gustchina A, Weber IT,. 1991. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10: 325-329.
108. Haas TL, Madri JA,. 1999. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc. Med. 9: 70-77. (Pubitemid 29512239)
109. Harenberg J,. 2009. New anticoagulants in atrial fibrillation. Semin Thromb Hemost. 35: 574-585.
110. Harth G, Andrews N, Mills AA, et al,. 1993. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol. Biochem. Parasitol. 58: 17-24.
111. Hawkins D,. 2003. Clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism. Am. J. Health Syst. Pharm. 60: 6-10.
112. He X, Rezaie AR,. 1999. Identification and characterization of the sodium-binding site of activated protein C. J. Biol. Chem. 274: 4970-4976.
113. Henriet P, Blavier L, Declerck Y,. 1999. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 107: 111-119. (Pubitemid 29133530)
114. Heras M, Chesebro JH, Penny WS, et al,. 1989. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79: 657-665. (Pubitemid 19087717)
115. Hernandez AA, Roush WR,. 2002. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol. 6: 459-465. (Pubitemid 34804768)
116. Hidalgo M, Eckhardt GS,. 2001. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93: 178-193. (Pubitemid 32166488)
117. Hiraoka N, Allen E, Apel IJ, et al,. 1998. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365-377. (Pubitemid 28507325)
118. Hirsh J, Warkentin TE, Shaughnessy SG, et al,. 2001. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119: 64-94.
119. Ho DD, Toyoshima T, Mo H, et al,. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68: 2016-2020. (Pubitemid 24065777)
120. Hofmann T, Hodges RS, James MN,. 1984. Effect of pH on the activities of penicillopepsin and Rhizopus pepsin and a proposal for the productive substrate binding mode in penicillopepsin. Biochemistry 23: 635-643.
121. Hong L, Treharne A, Hartsuck JA, et al,. 1996. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry 35: 10627-10633. (Pubitemid 26279641)
122. Hornak V, Simmerling C,. 2007. Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov. Today 12: 132-138. (Pubitemid 46176670)
123. Hotary KB, Allen ED, Brooks PC, et al,. 2003. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114: 33-45. (Pubitemid 36859839)
124. Hunkapiller MW, Richards JH,. 1972. Studies on the catalytic mechanism of pepsin using a new synthetic substrate. Biochemistry 11: 2829-2839.
125. Huntington JA,. 2003. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J. Thromb. Haemost. 1: 1535-1549.
126. Huntington JA, Baglin TP,. 2003. Targeting thrombin-rational drug design from natural mechanisms. Trends Pharmacol. Sci. 24: 589-595. (Pubitemid 37357143)
127. Huntington JA, Esmon CT,. 2003. The molecular basis of thrombin allostery revealed by a 1.8 Šstructure of the "slow" form. Structure 11: 469-479. (Pubitemid 36419573)
128. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB,. 2008. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal. 20: 1198-1208.
129. Hwang YS, Chmielewski J,. 2005. Development of low molecular weight HIV-1 protease dimerization inhibitors. J. Med. Chem. 48: 2239-2242. (Pubitemid 40396351)
130. Hyland LJ, Tomaszek TA, Meek TD,. 1991. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30: 8454-8463.
131. Inki P, Jalkanen M,. 1996. The role of syndecan-1 in malignancies. Ann. Med. 28: 63-67. (Pubitemid 26056048)
132. Itoh Y, Kajita M, Kinoh H, Mori H, Okada A, Seiki M,. 1999. Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol- anchored proteinase. J. Biol. Chem. 274: 34260-34266. (Pubitemid 129511766)
133. Itoh Y, Nagase H,. 2002. Matrix metalloproteinases in cancer. Essays Biochem. 38: 21-36. (Pubitemid 36589192)
134. Itow S, Camargo EPJ,. 1977. Proteolytic activites in cell extracts of Trypanosoma cruzi. J. Protozool. 24: 591-595. (Pubitemid 8237288)
135. Ivey ME, Little PJ,. 2008. Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. Thromb Res. 123: 288-297.
136. Jadhav PK, Ala P, Woerner FJ, et al,. 1997. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40: 181-191. (Pubitemid 27045074)
137. James MNG, Sielecki A, Saliturot F, et al,. 1982. Proc. Natl. Acad. Sci. USA 79: 6137.
138. James MNG, Sielecki AR,. 1985. Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. Biochemistry 24: 3701-3713. (Pubitemid 15011908)
139. Jochim AL, Miller SE, Angelo NG, Arora PS,. 2009. Evaluation of triazolamers as active site inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 19: 6023-6026.
140. Jones GC, Riley GP, Buttle DJ,. 2008. The role of proteases in pathologies of the synovial joint. Int. J. Biochem. Cell Biol. 40: 1199-1218.
141. Kadono Y, Shibahara K, Namiki M, et al,. 1998. Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in madin-darby canine kidney epithelial cells. Biochem. Biophys. Res. Commun. 251: 681-687. (Pubitemid 28512770)
142. Kahne D, Still WC,. 1988. Hydrolysis of a peptide bond in neutral water. J. Am. Chem. Soc. 110: 7529-7534.
143. Kaldor SW, Kalish VJ, Davies JF, et al,. 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40: 3979-3985. (Pubitemid 27512316)
144. Kaplan AH, Michael SF, Wehbie RS, et al,. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91: 5597-5601. (Pubitemid 24174375)
145. Karameris A, Panagou P, Tsilalis T, et al,. 1997. Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. Am. J. Respir. Crit. Care Med. 156: 1930-1936. (Pubitemid 28011804)
146. Katoh I, Yoshinaka Y, Rein A, et al,. 1985. Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology 145: 280-292. (Pubitemid 15016449)
147. Keillor J, Brown R,. 1992. Attack of Zwitterionic Thiolates on a distorted anilide as a model for the acylation of papain by amides. A simple demonstration of a bell-shaped PH-rate profile. J. Am. Chem. Soc. 114: 7983-7989.
148. Kelker MS, Page R, Peti W,. 2009. Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. J. Mol. Biol. 385: 11-21.
149. Kim EE, Baker CT, Dwyer MD, et al,. 1995. Crystal structure of HIV-1 protease in complex with Vx-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117: 1181-1182.
150. Kishore-Kumar GD, Chavarria GE, Charlton-Sevcik AK, Arispe WM, Macdonough MT, Strecker TE, Chen SE, Siim BG, Chaplin DJ, Trawick ML, Pinney KG,. 2010. Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg. Med. Chem. Lett. 20: 1415-1419.
151. Kohl NE, Emini EA, Schleif WA, et al,. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85: 4686-4690.
152. Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M,. 2000. Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Lett. 480: 142-146.
153. Kondo LM, Wittkowsky AK, Wiggins BS,. 2001. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann. Pharmacother. 35: 440-451. (Pubitemid 32260212)
154. Krem MM, Prasad S, Di Cera E,. 2002. Ser (214) is crucial for substrate binding to serine proteases. J. Biol. Chem. 277: 40260-40264. (Pubitemid 35215597)
155. Krem MM, Rose T, Di Cera E,. 1999. The C-terminal sequence encodes function in serine proteases. J. Biol. Chem. 274: 28063-28066.
156. Lam DK, Schmidt BL,. 2010. Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain 149: 263-272.
157. Lambert DM, Peteway SR Jr, McDanal CE, et al,. 1992. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob. Agents Chemother. 36: 982-988.
158. Lange UEW, Baucke D, Hornberger W, Mack H, Seitz W, Hoffke HW,. 2003. D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the p1moiety. Bioorg. Med. Chem. Lett. 13: 2029-2033. (Pubitemid 36638404)
159. Lecompte T, Toussaint-Hacquard M, Devignes J,. 2009. Les anticoagulants inhibiteurs directs de la thrombine. Ann Fr Anesth Reanim. 28 (Suppl 1): S3-S7.
160. Lefebvre E, Schiffer CA,. 2008. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10 (3): 131-142.
161. Lima APC, Tessier DC, Thomas DY, et al,. 1994. Identification of new cysteine protease gene isoforms in Trypanosoma cruzi. Mol. Biochem. Parasitol. 67: 333-338. (Pubitemid 24330745)
162. Linhardt RJ, Gunay NS,. 1999. Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25: 5-16. (Pubitemid 29517028)
163. Liotta LA, Stetler-Stevenson WG,. 1990. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1: 99-106.
164. Little SJ, Holte S, Routy JP, et al,. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347: 385-394. (Pubitemid 34851830)
165. Liu CY, Nossel HL, Kaplan KL,. 1979. The binding of thrombin by fibrin. J. Biol. Chem. 54: 10421-10425. (Pubitemid 10180980)
166. Lowe G, Williams A,. 1965. Direct evidence for an acylated thiol as an intermediate in papain- and ficin-catalysed hydrolyses. Biochem. J. 96: 189-193.
167. Lu D, Sham YY, Vince R,. 2010. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease. Bioorg. Med. Chem. 18: 2037-2048.
168. Lukacova V, Zhang Y, Mackov M, et al,. 2004. Similarity of binding sites
169. Mack H, Baucke D, Hornberger W, Lange UE, Seitz W, Höffken HW,. 2006. Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 16: 2641-2647.
170. Mac Kerrow JH, Sun E, Rosenthal PJ, et al,. 1993. The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol. 47: 821-853. (Pubitemid 23302954)
171. Major CD, Santulli RJ, Derian CK, et al,. 2003. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 23: 931-939. (Pubitemid 36713544)
172. Makela M, Sorsa T, Uitto VJ, et al,. 1998. The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration. Adv. Dent. Res. 12: 131-135.
173. Mansour K, Taher AT, Musallam KM, Alam S,. 2009. Aspirin resistance. Adv Hematol. 2009: 937352.
174. Maraganore JM, Bourdon P, Jablonski J, et al,. 1990. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29: 7095-7101. (Pubitemid 20241158)
175. Markwardt F,. 1991. Past, present and future of hirudin. Haemostasis 21: 11-26.
176. Marumo M, Wakabayashi I,. 2009. Sensitivity of thrombin-induced platelet aggregation to inhibition by ethanol. Clin Chim Acta. 402: 156-159.
177. Matheson AJ, Goa KL,. 2000. Desirudin: a review of its use in the management of thrombotic disorders. Drugs 60: 679-700.
178. Maupin-Furlow JA, Gil MA, Humbard MA, et al,. 2005. Archaeal proteasomes and other regulatory proteases. Curr. Opin. Microbiol. 8: 720-728. (Pubitemid 41643041)
179. McCammon JA,. 2005. Target flexibility in molecular recognition. Biochim. Biophys. Acta 1754: 22-224.
180. Mccawley LJ, Matrisian LM,. 2000. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today 6: 149-156. (Pubitemid 30171365)
181. Mcgrath ME, Eakin AE, Engel JC, et al,. 1995. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J. Mol. Biol. 247: 251-259.
182. Mckerrow JH, Sun E, Rosenthal PJ, et al,. 1993. The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol. 47: 821-853. (Pubitemid 23302954)
183. Mckerrow JH,. 1999. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. 29: 833.
184. McKerrow JH, Caffrey C, Kelly B, Loke P, Sajid M,. 2006. Proteases in parasitic diseases. Annu. Rev. Pathol. Mech. Dis. 1: 497-536.
185. Mengwasser KE, Bush LA, Shih P, et al,. 2005. Hirudin binding reveals key determinants of thrombin allostery. J. Biol. Chem. 280: 26997-27003. (Pubitemid 41040736)
186. Meredith JA, Wallberg H, Vrang L, Oscarson S, Parkes K, Hallberg A, Samuelsson B,. 2010. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors. Eur J Med Chem. 45: 160-170.
187. Miller M, Schneider J, Sathyanarayana BK, et al,. 1989. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246: 1149-1152. (Pubitemid 20012771)
188. Mittl PRE, Grütter MG,. 2006. Opportunities for sructure-based design of protease directed drugs. Curr. Opin. Struct. Biol. 16: 769-775. (Pubitemid 44827737)
189. Mizuno K, Nakamura T, Takada K, et al,. 1987. A membrane-bound, calcium-dependent protease in yeast alpha-cell cleaving on the carboxyl side of paired basic residues. Biochem. Biophys. Res. Commun. 144: 807-814. (Pubitemid 17078759)
190. Moser M, Patterson C,. 2003. Thrombin and vascular development: a sticky subject. Arterioscler. Thromb. Vasc. Biol. 23: 922-930. (Pubitemid 36713543)
191. Moy FJ, Chanda PK, Chen J, et al,. 2002. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc. 124: 12658-12659. (Pubitemid 35215979)
192. Murphy G, Houbrechts A, Cockett MI, et al,. 1991. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30: 8097-8102.
193. Murphy G, Nguyen Q, Cockett MI, et al,. 1994. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J. Biol. Chem. 269: 6632-6636. (Pubitemid 24191045)
194. Murta ACM, Perechini PM, Souto-Padron T, et al,. 1990. Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Mol. Biochem. Parasitol. 43: 27-38. (Pubitemid 20306265)
195. Musil D, Zucic D, Turk D, et al,. 1991. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10: 2321-2330. (Pubitemid 121000005)
196. Muzammil S, Ross P, Freire E,. 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42: 631-638. (Pubitemid 36133287)
197. Myers SA, Wolowacz RG,. 1998. Tetracycline-based MMP inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro. Adv. Dent. Res. 12: 86-93.
198. Nagai Y, Lapiere CM, Gross J,. 1966. Tadpole collagenase. Preparation and purification. Biochemistry 5: 3120-3130.
199. Nagase H, Woessner JF Jr., 1999. Matrix metalloproteinases. J. Biol. Chem. 274: 21491-21494.
200. Nakagawa H, Ohtaki S,. 1986. Cysteine proteinases and their inhibitors De Gryter: Berlin.
201. Nappi J,. 2002. The biology of thrombin in acute coronary syndromes. Pharmacotherapy 22: 90-96.
202. Nascimento AE, De Souza W,. 1996. High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture. Biol. Cell. 86: 53-58. (Pubitemid 26245124)
203. Niu W, Chen Z, Bush-Pelc LA, Bah A, Gandhi PS, Di Cera E,. 2009. Mutant N143P reveals how Na+ activates thrombin. J. Biol. Chem. 284: 36175-36185.
204. Nogami K, Zhou Q, Myles T, et al,. 2005. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J. Biol. Chem. 280: 18476-18481.
205. Nomura H, Sato H, Seiki M, et al,. 1995. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55: 3263-3266.
206. Nutescu EA, Shapiro NL, Chevalier A,. 2008. New anticoagulant agents: direct thrombin inhibitors. Card clinics. 26: 169-187. (Pubitemid 351506494)
207. Ofosu FA,. 2003. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfus. Apher. Sci. 28: 265-268. (Pubitemid 36506501)
208. Oh S, Chang W, Suh J,. 2001. An aspartic protease analogue: intermolecular catalysis of peptide hydrolysis by carboxyl groups. Bioorg. Med. Chem. Lett. 11: 1469-1472. (Pubitemid 32510845)
209. Ohtaka H, Freire E,. 2005. Adaptive inhibitors of the HIV-1 protease. Prog. Biophys. Mol. Biol. 88: 193-208. (Pubitemid 39568611)
210. Ohtaka H, Schon A, Freire E,. 2003. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 42: 13659-13666. (Pubitemid 37444916)
211. Olsen DB, Stahlhut MW, Rutkowski CA, et al,. 1999. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J. Biol. Chem. 274: 23699-23701.
212. Osipov AV, Filkin SY, Makarova YV, Tsetlin VI, Utkin YN,. 2010. A new type of thrombin inhibitor, noncytotoxic phospholipase A2, from the Naja haje cobra venom. Toxicon. 55: 186-194.
213. Otlewski J, Jelen F, Zakrzewska M, et al,. 2005. The many faces of protease-protein inhibitor Interaction. EMBO J. 24: 1303-1310. (Pubitemid 40593051)
214. Otto HH, Schirmeister T,. 1997. Cysteine proteases and their inhibitors. Chem. Rev. 97: 133-171. (Pubitemid 127662444)
215. Overall CM, Kleifeld O,. 2006. Tumour microenvironment opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6: 227-239. (Pubitemid 43292566)
216. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, et al,. 2003. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138: 620-626.
217. Palmeira VF, Kneipp LF, Alviano CS, dos Santos ALS,. 2006. Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: Effect of HIV aspartyl proteolytic inhibitors. Res. Microbiol. 157: 819-826. (Pubitemid 44559672)
218. Park H, Suh J, Lee S,. 2000. Ab initio studies on the catalytic mechanism of aspartic proteinases: nucleophilic versus general acid/ general base mechanism. J. Am. Chem. Soc. 122: 3901-3908. (Pubitemid 30241592)
219. Parry MA, Maraganore JM,. 1994. Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 33: 14807-14814.
220. Pavlaki M, Zucker S,. 2003. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22: 177-203. (Pubitemid 36561057)
221. Pender SL, MacDonald TT,. 2004. Matrix metalloproteinases and the gut: new roles for old enzymes. Curr. Opin. Pharmacol. 4: 546-550. (Pubitemid 40267866)
222. Perona J, Craik CS,. 1995. Structural basis of substrate specificity in the serine proteases. Protein Sci. 4: 337-360.
223. Petitou M, Duchaussoy P, Jaurand G, et al,. 1997. J. Med. Chem. 40: 1600-1607.
224. Polette M, Nawrocki-Raby B, Gilles C, et al,. 2004. Tumour invasion and matrix metalloproteinases. Crit. Rev. Oncol. Hematol. 49: 179-186. (Pubitemid 38251350)
225. Polgar L, Halasz P,. 1982. Current problems in mechanistic studies of serine and cysteine proteinases. Biochem. J. 207: 1-10.
226. Polgar L,. 1973. On the mode of activation of the catalytically essential sulfhydryl group of papain. Eur. J. Biochem. 33: 104-109.
227. Polticelli F, Zaini G, Bolli A, et al,. 2005. Probing the cruzain S2 recognition subsite: a kinetic and binding energy calculation study. Biochemistry 44: 2781-2789. (Pubitemid 40293654)
228. Powe D, Brough J, Carter G, et al,. 1997. TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br. J. Cancer 75: 1678-1683. (Pubitemid 27229061)
229. Poyarkov A, Rocabayera X, Poyarkova S, Kukha V,. 2008. Influence of aromatic and aliphatic moieties on thrombin inhibitors potency. Open Biochem. J. 2: 143-149.
230. Randolph JT, Huang PP, Flosi DJ, DeGoey D, Klein LL, Yeung CM, Flentge C, Sun M, Zhao C, Dekhtyar T, Mo H, Colletti L, Kati W, Marsh KC, Molla A, Kempf DJ,. 2006. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors. Bioorg. Med. Chem. 14: 4035-4046.
231. Rao JKM, Erickson JW, Wlodawer A,. 1991. Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 30: 4663-4671.
232. Redshaw S,. 1998. 1994. Inhibitors of HIV proteinase. Expert Opin. Investig. Drugs 3: 273-286. (Pubitemid 24093460)
233. Reiffel JA,. 2004. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? Curr. Opin. Cardiol. 19: 58-63. (Pubitemid 39115290)
234. Richards AD, Roberts R, Dunn BM, et al,. 1989. Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases. FEBS Lett. 247: 113-117. (Pubitemid 19092298)
235. Ridky T, Leis J,. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270: 29621-29623. (Pubitemid 26002151)
236. Roberts NA, Martin JA, Kinchington D, et al,. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248: 358-361.
237. Roberts NA,. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9: 27-32.
238. Robinson BS, Riccardi KA, Gong YF, et al,. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44: 2093-2099. (Pubitemid 30484432)
239. Rosencher N, Bellamy L, Arnaout L,. 2009. Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? Arch Cardiovasc Dis. 102: 327-333.
240. Roush WR, Gonzalez FV, McKerrow JH, et al,. 1998. Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain. Bioorg. Med. Chem. Lett. 8: 2809-2812. (Pubitemid 28496675)
241. Roy R, Zhang B, Moses MA,. 2006. Making the cut: protease-mediated regulation of angiogenesis. Exp. Cell Res. 312: 608-622. (Pubitemid 43290337)
242. Ryan ME, Ramamurthy NS, Golub LM,. 1998. Tetracyclines inhibit protein glycation in experimental diabetes. Adv. Dent. Res. 12: 152-158.
243. Sagi K, Nakagawa T, Yamanashi M, et al,. 2003. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids. J. Med. Chem. 46: 1845-1857. (Pubitemid 36532228)
244. Sajid M, Mckerrow JH,. 2002. Cysteine Proteases of Parasitic Organisms, Molecular and Biochemical Parasitology. Mol. Biochem. Parasitol. 120: 1-21. (Pubitemid 34159288)
245. Sanchez-Lopez R, Alexander CM, Behrendtsen O, et al,. 1993. Role of zinc-binding- and hemopexin domain-encoded sequences in the substrate specificity of collagenase and stromelysin-2 as revealed by chimeric proteins. J. Biol. Chem. 268: 7238-7247. (Pubitemid 23105614)
246. Šašková KG, KoÅíšek M, Lepšík M, Brynda J, Åezáčová P, Václavíková J, Kagan RM, Machala L, Konvalinka J,. 2008. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Sci. 17: 1555-1564.
247. Sato H, Kinoshita T, Takino T, et al,. 1996. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett. 393: 101-104. (Pubitemid 26298239)
248. Sato H, Takino T, Miyamori H,. 2005. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci. 96: 212-217. (Pubitemid 40767057)
249. Sato H, Takino T, Okada Y, et al,. 1994. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61-65. (Pubitemid 24216953)
250. Scharfstein J, Schechter M, Senna M, et al,. 1986. Trypanosoma cruzi: characterization and isolation of a 57/51 000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes. J. Immunol. 137: 1336-1341. (Pubitemid 16041125)
251. Scheidt KA, Roush WR, Mckerrow JH, et al,. 1998. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorg. Med. Chem. 6: 2477-2494. (Pubitemid 29002936)
252. Schmidt AE, Padmanabhan K, Underwood MC, et al,. 2002. Thermodynamic linkage between the S1 site, the Na+ site, and the Ca2+ site in the protease domain of human activated protein C (APC). Sodium ion in the APC crystal structure is coordinated to four carbonyl groups from two separate loops. J. Biol. Chem. 277: 28987-28995.
253. Schnapp AR, Eickhoff CS, Sizemore D, et al,. 2002. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect. Immun. 70: 5065-5074.
254. Shi SH, Chen JZ, Hu GD, Yi CH, Zhang SL, Zhang QG,. 2009. Molecular insight into the interaction mechanisms of inhibitors BEC and BEG with HIV-1 protease by using MM-PBSA method and molecular dynamics simulation. J. Mol. Struc: THEOCHEM. 913: 22-27.
255. Seelmeier S, Schmidt H, Turk V, et al,. 1988. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85: 6612-6616.
256. Seiki M,. 2002. The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr. Opin. Cell Biol. 14: 624-632. (Pubitemid 35247747)
257. Seiki M,. 2003. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194: 1.
258. Sham HL, Kempf DJ, Molla A, et al,. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42: 3218-3224. (Pubitemid 28553744)
259. Sheehan JP, Sadler JE,. 1994. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. USA 91: 5518-5522. (Pubitemid 24174359)
260. Shultz MD, Bowman MJ, Ham YW, et al,. 2000. Small-molecule inhibitors of HIV-1 protease dimerization derived from cross-linked interfacial peptides. Angew. Chem. Int. Ed. Engl. 39: 2710-2713. (Pubitemid 30629193)
261. Steinberg SF,. 2005. The cardiovascular actions of protease-activated receptors. Mol. Pharmacol. 67: 2-11. (Pubitemid 40069960)
262. Sternlicht MD, Werb Z,. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 1: 463.
263. Storer AC, Menard R,. 1994. Catalytic mechanism in papain family of cysteine peptidases. Meth. Enzymol. 244: 486-500.
264. Strongin AY,. 2010. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta. 1803: 133-141.
265. Stubbs MT, Bode W,. 1993. A model for the specificity of fibrinogen cleavage by thrombin. Semin. Thromb. Hemost. 19: 344-351. (Pubitemid 24023334)
266. Stubbs MT, Bode W,. 1993. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69: 1-58. (Pubitemid 23068230)
267. Stürzebecher J, Prasa D, Hauptmann J, et al,. 1997. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J. Med. Chem. 40: 3091-3099. (Pubitemid 27391541)
268. Suguna K, Padlan EA, Smith CW, et al,. 1987. Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc. Natl. Acad. Sci. USA 84: 7009-7013.
269. Suh J, Park TH, Hwang BK,. 1992. Comparable rates for cleavage of amide and ester bonds through nucleophilic attack by carboxylate anion and general acid catalysis by metal-bound water in a carboxypeptidase a model. J. Am. Chem. Soc. 114: 5141-5146.
270. Swanstrom R, Erona J,. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86: 145-170. (Pubitemid 30229899)
271. Takahashi K, Ikura M, Habashita H, et al,. 2005. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach. Bioorg. Med. Chem. 13: 4527-4543. (Pubitemid 40813241)
272. Takino T, Sato H, Yamamoto E, et al,. 1995. Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene 155: 293-298.
273. Tan JJ, Cong XJ, Hu LM, Wang CX, Jia L, Liang X,. 2010. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discovery Today, 15: 186-197.
274. Tang J, James MN, Hsu IN, et al,. 1978. Structural evidence for gene duplication in the evolution of the acid proteases. Nature 271: 618-621. (Pubitemid 8278939)
275. Tayebjee MH, Lip GYH, Blann AD, et al,. 2005. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Thromb. Res. 115: 205-208.
276. Tossi A, Bonin I, Antcheva N, et al,. 2000. Aspartic protease inhibitors. An integrated approach for the design andsynthesis of diaminodiol-based peptidomimetics. Eur. J. Biochem. 267: 1715-1722. (Pubitemid 30165525)
277. Toth M, Bernardo MM, Gervasi DC, et al,. 2000. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. J. Biol. Chem. 275: 41415-41423. (Pubitemid 32054977)
278. Trossini GH, Guido RV, Oliva G, Ferreira EI, Andricopulo AD,. 2009. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: Molecular modeling, CoMFA and CoMSIA studies. J Mol Graph Model 28: 3-11.
279. Turner SR, Strohbach JW, Tommasi RA, et al,. 1998. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41: 3467-3476. (Pubitemid 28406555)
280. Turk D, Guncar G, Podobnik M, Turk B,. 1998. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. 379: 137-147. (Pubitemid 28075973)
281. Ueno H, Nakamura H, Inoue M, et al,. 1997. Expression and tissue localization of membrane-types 1, 2 and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 5: 2055-2060. (Pubitemid 27209741)
282. UNAIDS. 2004. HIV rates up globally Asia particularly worrisome. Med. Health 58: 1.
283. Vandeputte-Rutten L, Gros P,. 2002. Novel proteases: common themes and surprising features. Curr. Opin. Struct. Biol. 12: 704-708. (Pubitemid 36009485)
284. Velazquez-Campoy A, Muzammil S, Ohtaka H, Schon A, et al,. 2003. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. 3: 311-328. (Pubitemid 38016620)
285. Vera DiVaio MAF, Freitas A, Castro H, Dealbuquerque S, Cabral L, Rodrigues, Albuquerque M, Martins R, Henriques M, Dias L,. 2009. Synthesis, antichagasic in vitro evaluation, cytotoxicity assays, molecular modeling and SAR/QSAR studies of a 2-phenyl-3-(1-phenyl-1H-pyrazol-4-yl)-acrylic acid benzylidene-carbohydrazide series. Bioorg. Med. Chem. 17: 295-302.
286. Vergnolle N,. 2005. Protease-activated receptors and inflammatory hyperalgesia. Mem. Inst. Oswaldo Cruz. 100: 173-176. (Pubitemid 40685459)
287. Vergnolle N,. 2009. Protease-activated receptors as drug targets in inflammation and pain. Pharmacol Ther. 123: 292-309.
288. Verkhivker G, Tiana G, Camilloni C, Provasi D, Broglia RA,. 2008. Atomistic Simulations of the HIV-1 Protease Folding Inhibition. Biophys. Journ. 95: 550-562.
289. Vogler EA, Siedlecki CA,. 2009. Contact activation of blood-plasma coagulation. Biomaterials. 30: 1857-1869.
290. Walenga JM,. 2002. An overview of the direct thrombin inhibitor argatroban. Pathophysiol. Haemost. Thromb. 32: 9-14. (Pubitemid 37449298)
291. Walker B, Lynas JF,. 2001. Strategies for the inhibition of serine proteases. Cell Mol Life Sci. 58: 596-624. (Pubitemid 32382260)
292. Wang Z, Castresana MR, Newman WH,. 2004. Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. J. Mol. Cell. Cardiol. 36: 49-56. (Pubitemid 38084790)
293. Ward RV, Atkinson SJ, Reynolds JJ, et al,. 1994. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem. J. 304: 263-269. (Pubitemid 24354254)
294. Wensing AM, van Maarseveen NM, Nijhuis M,. 2010. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res. 85: 59-74.
295. Weitz J,. 1994. New anticoagulant strategies: current status and future potential. Drugs 48: 485-497.
296. Weitz JI, Bates ER,. 2003. Direct thrombin inhibitors in cardiac disease. Cardiovasc. Toxicol. 3: 13-25. (Pubitemid 37039658)
297. Wei Y, Ma CM, Hattori M,. 2009. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity. Eur J Med Chem. 44: 4112-4120.
298. Wells CM, Di Cera E,. 1992. Thrombin is a Na+ activated enzyme. Biochemistry 31: 11721-11730.
299. West ML, Fairlie DP,. 1995. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 16: 67-75.
300. White CM,. 2005. Thrombin-directed inhibitors:pharmacology and clinical use. Am. Heart. J. 149: 54-60.
301. Whittaker M, Floyd CD, Brown P, et al,. 1999. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99: 2735-2776.
302. Will H, Atkinson SJ, Butler GS, et al,. 1996. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J. Biol. Chem. 271: 17119-17123. (Pubitemid 26244261)
303. Williamson RA, Marston FA, Angal S, et al,. 1990. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J. 268: 267-274. (Pubitemid 20193961)
304. Witting JI, Bourdon P, Brezniak DV, et al,. 1992. Thrombin-specific inhibition by and slow clevage of hirulog-1. Biochem. J. 283: 737-743.
305. Wittkowsky AK,. 2002. The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 22: 97-104.
306. Wlodawer A, Erickson JW,. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62: 543-585. (Pubitemid 23237881)
307. Wlodawer A, Miller A, Jaskolski M, et al,. 1989. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245: 616-621. (Pubitemid 19213338)
308. Wlodawer A, Vondrasek J,. 1998. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27: 249-284. (Pubitemid 28286016)
309. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ,. 1997. Matrix metalloproteinase inhibitors. Invest. New Drugs 15: 61-75. (Pubitemid 27217752)
310. Wu Q, Kuo H, Deng GG,. 2005. Serine proteases and cardiac function. Biochim. Biophys. Acta 1751: 82-94. (Pubitemid 41033298)
311. Yana I, Weiss SJ,. 2000. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol. Biol. Cell. 11: 2387-2401. (Pubitemid 30489922)
312. Yan YL, Miller MT, Cao Y, Cohen SM,. 2009. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett. 19: 1970-1976.
313. Yoshiji H, Gomez D, Horgeirsson U,. 1996. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Br. J. Cancer 69: 131-154.
314. Zanatta N, Amaral SS, dos Santos JM, Mello DL, Fernandes LS, Bonacorso HG, Martins MAP, Andricopulo AD, Borchhardt DM,. 2008. Convergent synthesis and cruzain inhibitory activity of novel 2-(N'-benzylidenehydrazino)-4- trifluoromethyl-pyrimidines. Bioorg. Med. Chem. 16: 10236-10243. (Pubitemid 50324213)
315. Zeng Z, Cohen A, Zhang Z, et al,. 1995. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin. Cancer Res. 1: 899-906.
316. Zhang E, Tulinsky A,. 1997. The molecular environment of the Na+ binding site of thrombin. Biophys. Chem. 63: 185-200. (Pubitemid 27140429)
317. Zoete V, Michielin O, Karplus M,. 2002. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. J. Mol. Biol. 315: 21-52. (Pubitemid 34722109)
318. Zucker S, Pei D, Cao J, et al,. 2003. Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top Dev. Biol. 54: 1-74. (Pubitemid 137639464)